Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Nicolas Gendron: Real-World Data on Danaparoid in Patients with Suspected HIT
Nicolas Gendron/researchgate.net
Sep 1, 2026, 09:16

Nicolas Gendron: Real-World Data on Danaparoid in Patients with Suspected HIT

Nicolas Gendron, Postdoctorate research Fellow at Harvard Medical School, Research Fellow and Hematologist at Boston Children’s Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Haematologica Journal, adding:

“Real-world data on danaparoid in patients with suspected HIT

We are proud to share our latest work published in Haematologica Journal, conducted within the HIT Team of the Hôpital Européen Georges Pompidou (Paris), based on 6 years of consecutive real-world practice.

HIT (heparin-induced thrombocytopenia) is a rare but life-threatening immune-mediated prothrombotic disorder. When suspected, heparin must be stopped immediately and replaced by an alternative anticoagulant.

Danaparoid is one of the 2 main options available in France yet real-world data on its outcomes and biological monitoring remain surprisingly scarce.

Main results:

  • Thrombotic events occurred in 12% of patients
  • Bleeding events occurend in 10% of patients.

Both regardless of whether HIT was ultimately confirmed or not.

  • Low first anti-Xa activity and prolonged time below target anti-Xa were associated with thrombosis
  • Outcomes were similar in confirmed and non-confirmed HIT patients, reinforcing that suspected HIT must be treated promptly, without waiting for platelet functional assay results.

HIT remains a prothrombotic disorder with substantial morbidity despite anticoagulation.

  • Danaparoid remains a valid and effective option in acute HIT
  • Our findings underscore the need for therapeutic dosing until diagnosis is confirmed, along with anti-Xa monitoring to mitigate thrombotic risk.

Huge thanks to all co-authors, the HIT Team, and the hematology and clinical teams at HEGP․”

Title: Bleeding, thrombosis, and anti-Xa monitoring in danaparoid-treated patients with suspected heparin-induced thrombocytopenia: a retrospective single-center study

Authors: Nicolas Gendron, Carla Rial, Christine Le Beller, Aurélie Sarthou, Armand Schmeltz, Shaya Sable, Laetitia Mauge, Aurélien Philippe, Lina Khider, Maude Laney, Roya Nili, Anne Godier, Jean Luc Diehl, Pascale Gaussem, Emmanuelle Florens, Olivier Sanchez, Richard Chocron, Dominique Helley, David M. Smadja, Agnès Lillo-Le Louet

Nicolas Gendron: Real-World Data on Danaparoid in Patients with Suspected HIT

Stay updated with Hemostasis Today.

Agnès Lillo-Le Louet Anne Godier Armand Schmeltz Aurélie Sarthou Aurélien Philippe Carla Rial Christine Le Beller Danaparoid David M. Smadja Dominique Helley Emmanuelle Florens Haematologica Journal Health Hematology Hemostasis Hemostasis News Hemostasis Today heparin-induced thrombocytopenia HIT Jean-Luc Diehl Laetitia Mauge Lina Khider Maude Laney Medicine Nicolas Gendron Olivier Sanchez Pascale Gaussem Richard Chocron Roya Nili Shaya Sable
NewsFeed